Navigation Links
Three-Time Gold Medalist Misty May-Treanor Teams Up with Abreva to Knock Out Cold Sores this Cold and Flu Season
Date:12/6/2012

PARSIPPANY, N.J., Dec. 6, 2012 /PRNewswire/ -- GlaxoSmithKline Consumer Healthcare today announced it is teaming up with Misty May-Treanor, three-time Olympic gold medalist in beach volleyball, in a campaign to knock out the myths about cold sores. According to a new survey, the majority of Americans (63 percent) cannot correctly distinguish between cold sore myths and facts, and with cold and flu season approaching and cold sore triggers all around, it's more important than ever to know how to fight cold sores fast.

(Photo: http://photos.prnewswire.com/prnh/20121206/NY24707)

The survey, conducted by Wakefield Research on behalf of Abreva®, also revealed that nearly 7 in 10 (68 percent) Americans value faster healing time over lowest price when purchasing a medication. Abreva® is clinically proven to heal cold sores fast and is the number one over-the-counter cold sore treatment recommended by pharmacists.

"I've gotten cold sores for as long as I can remember and they always seem to pop up at the worst possible time. And for me, that was right in the middle of the 2012 London Games," says Misty May-Treanor, professional beach volleyball player and three-time Olympic gold medalist. "I have been using Abreva® for years, and I stick with it because it heals my cold sores fast. When I get a cold sore, I don't tough it out, I knock it out with Abreva®."

The survey revealed over half of respondents (52 percent) are unaware that cold sores go through multiple stages of development before beginning to heal, and one in two did not realize that if left untreated, cold sores can take up to two weeks to heal.  Abreva® heals cold sores much like a prescription would but without the hassle. It penetrates deep to the root of a cold sore and helps block the spread of the virus to healthy cells.

"Other 'look-alike' cold sore treatments claim to heal cold sores as fast as Abreva® and may even imitate the packaging, but Abreva® is the only over-the-counter medication approved by the FDA that is proven to shorten healing time and duration of a cold sore," said Pam Marquess, Pharm.D, pharmacist, pharmacy chain owner and GSK spokesperson. "We're heading into prime cold sore season, with triggers like cold winter weather, cold/flu season and even stress of the upcoming holidays upon us.  So if you're one of the 80 million Americans who suffer from cold sores, be prepared to knock out your cold sores fast with Abreva®."

Abreva® is available at retailers nationwide and comes with a risk free guarantee. If you aren't completely satisfied with Abreva® for any reason, save your receipt and remaining product, and call 1-877-709-3539 to get your money back. For more information about Abreva®, please visit www.Abreva.com.

About Cold Sores
A cold sore is a blister that forms on or around the lips and is usually caused by the Herpes Simplex Virus (HSV-1). HSV-1 usually affects the lips or mouth but can spread to the eyes or genitals. Most cold sore sufferers aren't exactly sure when they first encountered the virus because HSV-1 is usually contracted early in childhood.  While it's likely that 90 percent of adults have been infected by the cold sore virus, not everyone gets cold sore outbreaks. Actually, only 20 percent to 40 percent of people will experience cold sores.

About Abreva®
Abreva is the only FDA-approved over-the-counter product to speed the healing of cold sores. Abreva contains 10 percent docosanol.   About GlaxoSmithKline Consumer Healthcare
GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its well-known brands include Nicorette® and NicoDerm® CQ, the leading smoking cessation products;  alli, the only FDA-OTC weight loss aid; as well as medicine cabinet staples, Aquafresh®, Sensodyne®, Tums®, and Breathe Right®, all of which are trademarks owned by and/or licensed to GlaxoSmithKline Group of Companies.

About GlaxoSmithKline®
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: GSK.com.

Misty May-Treanor and Pam Marquess are paid spokespeople for Abreva® but their opinions are their own.  Media Relations: GSK Consumer Healthcare

Deborah Bolding

deborah.g.bolding@gsk.com

(973) 889-2344Edelman

 

Catherine McCormack

catherine.mccormack@edelman.com 

(212) 819-4816
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sony Medical Division Teams with Wills Eye Institute to Bring "Expert" Panel of Ophthalmologists to AAO 2012 Convention
2. A Successful Launch of a New Oncology Product Requires Global Teams & Planning
3. Eaton Scientific Teams Up with Renowned Womens Sexual Health Expert Dr. Jennifer R. Berman, MD and Berman Sexual Health to Advance Tropine 3 Trials and Marketing
4. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
5. eCardio Teams Up with Heart Rhythm Society for Month-Long Campaign to Raise Awareness of Cardiac Arrhythmias
6. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
7. L.S.E. (Barcelona) anuncia la primera financiación del antiplaquetario NmC por inversores españoles y suizos
8. National Community Pharmacists Association and Purdue Pharma Urge Americans to Safeguard Rx Medicines This Holiday Season
9. Perfect Your Holiday Look this Season with the BMR Facial Toner
10. Skip the Seasonal Blues: Learn how Probiotic Health Benefits Kick-Start Digestive Support
11. BI-LO Offers Health Giveaways With Flu Vaccinations, Encourages Community To Shield Their Health This Flu Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. ... ... ... ... Astellas is a ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):